Home>>Cisapride-d6

Cisapride-d6

Catalog No.GC46120

A neuropeptide with diverse biological activities

Products are for research use only. Not for human use. We do not sell to patients.

Cisapride-d6 Chemical Structure

Cas No.: N/A

Size Price Stock Qty
1mg
$427.00
In stock
5mg
$1,707.00
In stock

Tel:(909) 407-4943 Email: sales@glpbio.com

Customer Reviews

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

Cisapride-d6 is intended for use as an internal standard for the quantification of cisapride by GC- or LC-MS. Cisapride is an agonist of serotonin (5-HT) receptor subtype 5-HT4 (IC50 = 0.483 μM in COS-7 cells expressing the human receptor).1 It induces relaxation of precontracted isolated rat esophageal thoracic muscularis mucosae preparations (EC50 = 102.33 nM). Cisapride (0.5 mg/kg) increases the rate of gastric emptying in rats. It is also a human ether-a-go-go related gene (hERG) channel blocker that binds to hERG channels with an IC50 value of less than 1 μM in a fluorescence polarization assay. Formulations containing cisapride have previously been used in the treatment of nocturnal heartburn associated with gastroesophageal reflux disease.

|1. Park, J.S., Im, W., Choi, S., et al. Discovery and SAR of N-(1-((substituted piperidin-4-yl)methyl)-3-methoxypiperidin-4-yl)-2-methoxybenzamide derivatives: 5-Hydroxytryptamine receptor 4 agonist as a potent prokinetic agent. Eur. J. Med. Chem. 109, 75-88 (2016).

Reviews

Review for Cisapride-d6

Average Rating: 5 ★★★★★ (Based on Reviews and 17 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Cisapride-d6

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.